Stockreport

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

NervGen Pharma Corp. - Common stock  (NGEN) 
PDF Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chroni [Read more]